Inspire Medical (INSP) news
Recent news
Inspire Medical Systems, Inc.: Truist Securities raises target price to $78 from $62
Truist Securities has raised its price target for Inspire Medical Systems, Inc. (INSP) to $78 from $62, while maintaining its "Hold" rating . This adjustment reflects the firm’s updated assessment of the company’s growth prospects and market dynamics. The move follows a series of analyst actions…
AInvest Wire · 11h agoInspire Medical Systems, Inc.: Leerink partners raises target price to $67 from $59
Leerink Partners has revised its price target for Inspire Medical Systems, Inc. (NASDAQ: RESN), raising it to $67 from $59, reflecting updated expectations for the company’s financial performance and market positioning. The adjustment follows recent developments in the company’s product pipeline…
AInvest Wire · 5d agoInspire Medical Systems, Inc.: RBC raises target price to $75 from $60
RBC Capital Markets has raised its price target for Inspire Medical Systems, Inc. (INSP) to $75 from $60, citing the company’s growth potential and recent performance. The stock closed at $69.36 on September 29, 2026, reflecting a 5.22% decline from the previous day’s close, though it has since…
AInvest Wire · Oct 1, 2026Trace Medical Q2 revenue USD 45.376 million vs. IBES estimate USD 44 million
Inspire Medical Systems (INSP) reported second-quarter revenue of $200.58 million, surpassing the Zacks Consensus Estimate of $197.63 million by 2.95%. This represents a decline compared to the same period in 2025, when the company generated $217.09 million in revenue. Despite the year-over-year…
AInvest Wire · Aug 7, 2026Inspire Medical Systems Inc: Truist Securities raises target price to $62 from $54
Truist Securities has raised its price target for Inspire Medical Systems Inc. (NYSE: INSP) to $62 from $54, maintaining a "Hold" rating on the stock . This adjustment reflects the firm’s updated assessment of the company’s financial performance and strategic outlook. Inspire Medical Systems, a…
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.